Evaxion Biotech Net Income Over Time
| EVAX Stock | USD 3.31 0.09 2.65% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Evaxion Biotech Performance and Evaxion Biotech Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evaxion Biotech. Projected growth potential of Evaxion fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Evaxion Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.00) | Revenue Per Share | Quarterly Revenue Growth 1.483 | Return On Assets | Return On Equity |
The market value of Evaxion Biotech AS is measured differently than its book value, which is the value of Evaxion that is recorded on the company's balance sheet. Investors also form their own opinion of Evaxion Biotech's value that differs from its market value or its book value, called intrinsic value, which is Evaxion Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evaxion Biotech's market value can be influenced by many factors that don't directly affect Evaxion Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Evaxion Biotech's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Evaxion Biotech should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Evaxion Biotech's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Evaxion Biotech AS and related stocks such as Reviva Pharmaceuticals, Mural Oncology Plc, and Annovis Bio Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVPH | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (846.8 K) | (3.8 M) | (8.5 M) | (24.3 M) | (39.3 M) | (29.9 M) | (26.9 M) | (25.6 M) |
| ANVS | (369.6 K) | (4.7 M) | (8.3 M) | (682.3 K) | (682.3 K) | (682.3 K) | (682.3 K) | (682.3 K) | (713.9 K) | (991 K) | (5.5 M) | (14.5 M) | (25.1 M) | (56.2 M) | (24.6 M) | (22.1 M) | (21 M) |
| PYPD | (1.8 M) | (1.8 M) | (1.8 M) | (3.9 M) | (8.2 M) | (8.2 M) | (11.4 M) | (54.5 M) | 5.9 M | (6.9 M) | (35.3 M) | (40.7 M) | (39.5 M) | (23.9 M) | (29 M) | (26.1 M) | (27.4 M) |
| GBIO | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (60.3 M) | (76.5 M) | (114.7 M) | (132.1 M) | (126.6 M) | (131.7 M) | (118.5 M) | (124.4 M) |
| BCAB | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29.8 M) | (35.9 M) | (95.4 M) | (105.3 M) | (123.5 M) | (69.8 M) | (62.8 M) | (65.9 M) |
| VERU | 300 K | 15.3 M | 14.3 M | 2.4 M | 4.3 M | 344.7 K | (6.6 M) | (23.9 M) | (12 M) | (19 M) | 7.4 M | (83.8 M) | (93.2 M) | (37.8 M) | (22.7 M) | (20.5 M) | (19.4 M) |
| SABS | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | 20.1 M | (17.1 M) | (18.7 M) | (42.2 M) | (34.1 M) | (30.7 M) | (29.2 M) |
| CELU | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (1.1 K) | (211.9 M) | (208.2 M) | (100.1 M) | 14.2 M | (196.3 M) | (57.9 M) | (66.6 M) | (69.9 M) |
| BTAI | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (2.1 M) | (4.5 M) | (19.3 M) | (32.3 M) | (82 M) | (106.6 M) | (165.8 M) | (179.1 M) | (59.6 M) | (53.6 M) | (56.3 M) |
Evaxion Biotech AS and related stocks such as Reviva Pharmaceuticals, Mural Oncology Plc, and Annovis Bio Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Evaxion Biotech AS financial statement analysis. It represents the amount of money remaining after all of Evaxion Biotech AS operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Evaxion Biotech AS | EVAX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Dr Neergaards Vej, |
| Exchange | NASDAQ Exchange |
USD 3.31
Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.